Summary
The Fourth Circuit held that the Lanham Act does not require a plaintiff asserting false association or false advertising claims under Section 43(a) to have used its own mark in United States commerce. The court concluded that the district court improperly dismissed Bayer's claims and reversed the cancellation ruling concerning Belmora's FLANAX registration. The judgment was vacated and the case was remanded for further proceedings.
Topics
Practice areas
Questions Presented
- Whether a plaintiff may bring false-association and false-advertising claims under Lanham Act § 43(a) without having previously used the asserted mark in United States commerce.
- Whether Bayer adequately pleaded that Belmora's alleged deception caused an injury within the Lanham Act's zone of interests and proximately caused economic or reputational harm.
- Whether a petitioner may seek cancellation under Lanham Act § 14(3) without having used the challenged mark in United States commerce.
- Whether the district court erred in dismissing Bayer's § 43(a) claims and reversing the TTAB's cancellation order.
Holdings
- Lanham Act § 43(a) does not require the plaintiff to have previously used its own mark in United States commerce. The statute requires use in commerce by the defendant of the offending mark or misrepresentation, while the plaintiff must allege that it believes it is or is likely to be damaged.
- Bayer adequately pleaded § 43(a) claims because its allegations placed the claims within the Lanham Act's zone of interests and plausibly alleged economic injury proximately caused by Belmora's deceptive use of the FLANAX mark and related advertising.
- Lanham Act § 14(3) does not require the cancellation petitioner to have used the challenged mark in United States commerce. BCC adequately pleaded a § 14(3) claim because its allegations placed the claim within the Lanham Act's zone of interests and plausibly alleged proximate injury from Belmora's deliberate misrepresentation of the source of its goods.
Key quotations
“We do not ask whether in our judgment Congress should have authorized Static Control’s suit, but whether Congress in fact did so. Just as a court cannot apply its independent policy judgment to recognize a cause of action that Congress has denied, it cannot limit a cause of action that Congress has created merely because ‘prudence’ dictates.” (819 F.3d at 704)
“It is important to emphasize that this is an unfair competition case, not a trademark infringement case.” (819 F.3d at 706)
“In sum, the Lanham Act’s plain language contains no unstated requirement that a § 43(a) plaintiff have used a U.S. trademark in U.S. commerce to bring a Lanham Act unfair competition claim.” (819 F.3d at 708)
“But trademark rights do not include using the mark to deceive customers as a form of unfair competition, as is alleged here.” (819 F.3d at 715)
Factual background
Bayer Consumer Care AG owned and sold the FLANAX brand for naproxen sodium pain relievers in Mexico and other Latin American countries, but did not market or sell FLANAX in the United States. Belmora LLC began selling FLANAX naproxen sodium products in the United States in 2004 and registered the mark in 2005. Bayer alleged that Belmora copied the appearance of Bayer's Mexican packaging and used marketing statements implying that its product was the same FLANAX product known and trusted in Mexico, causing consumers, distributors, and vendors to believe that the products were the same or affiliated.
Procedural history
BCC petitioned the TTAB to cancel Belmora's FLANAX registration, and the TTAB ordered cancellation under Lanham Act § 14(3) after finding that Belmora had misrepresented the source of its goods. Bayer separately sued under Lanham Act § 43(a), and the proceedings were consolidated in the Eastern District of Virginia after transfer. The district court dismissed Bayer's § 43(a) claims and reversed the TTAB's cancellation decision, concluding that Bayer lacked a cognizable claim because it had not used FLANAX in United States commerce. The Fourth Circuit vacated and remanded.
Remand instructions
Remanded to the Eastern District of Virginia for further proceedings consistent with the opinion, including allowing Bayer to proceed with its § 43(a) false-association and false-advertising claims and its § 14(3) cancellation claim. Any remedy should be determined by the district court upon proper evidence and should account for Belmora's ownership of the United States mark.